Biogen (BIIB) Revenue (2009 - 2026)

Biogen has reported Revenue for 18 years, with the latest figure at $2.7 billion in Q2 2026.

• On a quarterly basis, Revenue rose 3.42% year-over-year to $2.7 billion in Q2 2026; TTM through Jun 2026 was $10.0 billion, a 0.31% change from a year earlier, with the FY2025 full-year figure at $9.9 billion, up 2.22% from the prior year.
• Revenue was $2.7 billion for Q2 2026 at Biogen, up from $2.5 billion in the prior quarter.
• The five-year high for Revenue was $2.7 billion in Q2 2026, with the low at $2.3 billion in Q4 2025.
• Average Revenue over 5 years is $2.5 billion, with a median of $2.5 billion recorded in 2024.
• The sharpest annual moves came in 2022 and 2025: Revenue dropped 9.73% in 2022, then increased 7.33% in 2025.
• Over 5 years, Revenue stood at $2.5 billion in 2022, then retreated by 6.2% to $2.4 billion in 2023, then advanced by 2.87% to $2.5 billion in 2024, then slipped by 7.14% to $2.3 billion in 2025, then gained by 20.03% to $2.7 billion in 2026.
• The last three Revenue figures came in at $2.7 billion (Q2 2026), $2.5 billion (Q1 2026), and $2.3 billion (Q4 2025), per Business Quant data.